Ohr Pharmaceutical to Present at the 17th Annual BIO CEO & Investor Conference and Leerink Global Healthcare Conference in New York
February 09, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive...
Ohr Pharmaceutical Prices $25,000,000 Public Offering of Common Stock
February 06, 2015 08:30 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 6, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced the pricing of its previously announced underwritten...
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock
February 05, 2015 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it intends to offer its common stock in an...
Ohr Pharmaceutical Appoints Jason Slakter, MD, Chief Medical Officer, to Board of Directors
January 08, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Jason Slakter, MD, Chief Medical Officer, has...
Ohr Pharmaceutical Reports Fiscal Year 2014 Financial and Business Results
December 22, 2014 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its fiscal year ended September 30,...
Ohr Pharmaceutical to Announce Fiscal 2014 Financial Results and Host Conference Call on Monday, December 22
December 19, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced that it will report its...
Ohr Pharmaceutical to Present at the Oppenheimer & Co., Inc. 25th Annual Healthcare Conference
December 02, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive...
Ohr Pharmaceutical to Host Key Opinion Leader Meeting and Webcast on October 31 in New York City
October 27, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will host a Key Opinion Leader analyst...
Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting
October 20, 2014 07:15 ET
|
Ohr Pharmaceutical, Inc.
Reduction of Subretinal Hyperreflective Material (SHRM) Induced by OHR-102 Correlates With Improved Vision Outcomes
Regression of the SHRM Biomarker in Wet-AMD and Vision Improvement is Consistent...
Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD
October 14, 2014 07:15 ET
|
Ohr Pharmaceutical, Inc.
Primary Endpoint for Approval to be Based on Visual Acuity Improvements at 9 Months
Phase III Trials to Commence in the First Half of 2015
NEW YORK, Oct. 14, 2014 (GLOBE NEWSWIRE) -- Ohr...